Haemonetics (HAE)
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
$102.92+0.07%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · HAE
Next print, the company's guidance track record, and the earnings events we've seen in the last few years.
Likelihood the company beats analyst consensus on its next print. Read from its own beat history plus how sector peers have been reporting. Not a price-direction call: a serial beater often has the beat already priced in.
Prints it beat consensus, recent quarters.
Indicative, not a guarantee. Base rate ~71%.
Industry peers that beat since this name last reported.
Management's most recent EPS guidance action.
expected = 0.35*own_median(4.7) + peer(0.2*0.4) + term(2.0) → 3.73% (capped ±15.0)
Average absolute move on past earnings days.
Annualized: recent baseline volatility.
Of the last 0 guided quarters.
Actual vs. guided EPS, signed.
Excess return vs. sector ETF, day after print.
Earnings prints and pre-announcements detected in the SEC filing stream.
Results of Operations and Financial Condition. On August 6, 2026, Haemonetics Corporation issued a press release announcing financial results for the first quarter ended June 27, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The foregoing information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subjec…
Quarterly EPS and revenue actuals vs. consensus across the last eight quarters (including beat/miss size and the forward consensus heading into the next print) are on the way.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Results of Operations and Financial Condition. On May 7, 2026, Haemonetics Corporation issued a press release announcing financial results for the fourth quarter and fiscal year ended March 28, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The foregoing information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or o…
Results of Operations and Financial Condition. On February 5, 2026, Haemonetics Corporation issued a press release announcing financial results for the third quarter and nine months ended December 27, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The foregoing information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act…
Results of Operations and Financial Condition. On November 6, 2025, Haemonetics Corporation issued a press release announcing financial results for the second quarter ended September 27, 2025 and first half of fiscal 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The foregoing information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (t…
Results of Operations and Financial Condition. On August 7, 2025, Haemonetics Corporation issued a press release announcing financial results for the first quarter ended June 28, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The foregoing information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subjec…
Results of Operations and Financial Condition. On May 8, 2025, Haemonetics Corporation (the “Company”) issued a press release announcing financial results for the fourth quarter and fiscal year ended March 29, 2025. A copy of the press release is furnished with this report as Exhibit 99.1. The foregoing information, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to…
Results of Operations and Financial Condition. On February 6, 2025, Haemonetics Corporation issued a press release announcing financial results for the third quarter and nine months ended December 28, 2024. A copy of the press release is furnished with this report as Exhibit 99.1. The foregoing information, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabi…
Results of Operations and Financial Condition. On November 7, 2024, Haemonetics Corporation issued a press release announcing financial results for the second quarter ended September 28, 2024 and first half of fiscal 2025. A copy of the press release is furnished with this report as Exhibit 99.1. The foregoing information, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subj…
Results of Operations and Financial Condition. On August 8, 2024, Haemonetics Corporation issued a press release announcing financial results for the first quarter ended June 29, 2024. A copy of the press release is furnished with this report as Exhibit 99.1. The foregoing information, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section…
Results of Operations and Financial Condition. On May 9, 2024 , Haemonetics Corporation issued a press release announcing financial results for the fourth quarter and fiscal year ended March 30, 2024. A copy of the press release is furnished with this report as Exhibit 99.1. The foregoing information, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities…